Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma

Agios Pharmaceuticals 06.03.2017

Agios Appoints David Scadden, M.D., to the Board of Directors

Agios Pharmaceuticals 05.31.2017

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

Agios Pharmaceuticals 04.27.2017

Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene

Agios Pharmaceuticals 03.13.2017

FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

Agios Pharmaceuticals 03.01.2017

Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017

Agios Pharmaceuticals 01.09.2017

Agios Appoints Ian Clark to Board of Directors

Agios Pharmaceuticals 01.03.2017

Flagship Awards CEO of Agios Pharmaceuticals the Entrepreneur of the Year Award

Agios Pharmaceuticals 11.21.2016

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

Agios Pharmaceuticals 03.30.2016

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

Agios Pharmaceuticals 02.18.2016

Loading